SecBot SecBot
6-K ·Filed Apr 13, 2026

BNTX

BioNTech SE
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago SEC0001776985-26-000027
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong Phase 2 data in a difficult-to-treat population with FDA designations already in place significantly de-risks the path to approval. Triggers potential for near-term value inflection with planned 2026 BLA filing. Monitor for Phase 3 readout in breast cancer (DYNASTY-Breast02) later this year which could expand the market opportunity.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$96.70
T+0 close · Apr 13, 2026 · via day close
Latest settled
−3.28%
T+60 · $93.53
Vs SPY
−12.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $96.70entry
  2. T+1 · 7mo ago +1.77%α +0.56% · $98.41
  3. T+5 · 7mo ago +8.78%α +5.48% · $105.19
  4. T+20 · 6mo ago −3.47%α −11.20% · $93.34
  5. T+60 · 4mo ago −3.28%α −12.20% · $93.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech announced positive Phase 2 results for trastuzumab pamirtecan in HER2-expressing endometrial cancer, showing a 47.9% confirmed objective response rate and 8.1-month median progression-free survival. The data support advancement toward a 2026 BLA filing, with a confirmatory Phase 3 trial ongoing.

Key Facts

  • Trastuzumab pamirtecan met primary efficacy endpoint in Phase 2 cohort of 145 patients with HER2-expressing, recurrent endometrial cancer
  • Confirmed objective response rate was 47.9% in centrally tested patients (n=96) with median progression-free survival of 8.1 months
  • Drug showed activity across all HER2 expression levels including IHC1+ and IHC2+, addressing high unmet need where standard chemo has only 15% response rate
  • Safety profile was manageable with 46.9% grade 3 treatment-related adverse events and 4.8% grade 3 interstitial lung disease
  • Fast Track and Breakthrough Therapy designations received from FDA in 2023; BLA planned for 2026 subject to regulatory feedback

Financial Impact

Significant potential revenue upside from a new oncology product in a high-unmet-need population with potential for accelerated approval. Phase 3 trial Fern-EC-01 ongoing.

revenuepipeline valueR&D efficiency

Risk Factors

  • Phase 3 confirmatory trial (Fern-EC-01) must validate these results for full approval
  • Safety signals including 4.8% grade 3 ILD require careful risk-benefit assessment in broader populations
  • Competition from other HER2-targeted therapies in development

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000027
Document: form6-ktpamecdatasgo202613.htm0001776985-26-000027
Document: 0001776985-26-000027-index-headers.html0001776985-26-000027
Document: 0001776985-26-000027-index.html0001776985-26-000027
Document: 0001776985-26-000027.txt0001776985-26-000027

Track record

38 reports on BNTX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026